Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET
Company Participants
Rick Winningham – Chief Executive Officer
Rhonda Farnum – Chief Business Officer
Aziz Sawaf – Chief Financial officer
Aine Miller – Head-Development
Conference Call Participants
Marc Frahm – TD Cowen
Operator
Hello, ladies and gentlemen. Good afternoon. I would like to welcome everyone to the Theravance Biopharma First Quarter 2025 Conference Call. [Operator Instructions] Also, today’s conference is being recorded.
And now, I would like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir.
Rick Winningham
Good afternoon, and welcome to Theravance Biopharma’s First Quarter 2025 Earnings Results Conference Call.
On Slide 2, you will find our forward-looking statements disclaimer, which covers certain risk factors, which could cause actual results to differ materially from any forward-looking statements we might make in today’s call and which are described further in our filings with the SEC.
Moving to Slide 3. I’m joined today by Rhonda Farnum, Chief Business Officer; Aine Miller, Head of Development; and Aziz Sawaf, Chief Financial Officer.
Moving to Slide 4 and beginning on the left-hand side, YUPELRI delivered solid results in the first quarter with net sales increasing 6% to just over $58 million. This performance was driven by a similar increase in demand, as well as favorable pricing and channel mix. Building on the strong momentum we experienced in 2024, hospital doses increased 48% year-on-year. We are steadily advancing the CYPRESS trial, consistent with our objective of enrolling the right patients at high-performing sites and are pleased to be nearing the completion of the planned enrollment into the open-label portion of the study.
Shifting to the randomized withdrawal portion of the study, we are laser-focused on ensuring that we optimize those factors that are within
Read the full article here